PRISM BioLab and Receptor.AI Partner for AI Drug Discovery
TOKYO, Japan & CAMBRIDGE, Mass., March 13, 2026 PRISM BioLab Co., Ltd. and Receptor.AI Inc. have announced a strategic...
Vaccines, Blood & Biologics
Vima Therapeutics Doses First Patient in Phase 2 Trial
CAMBRIDGE, Mass., March 11, 2026 Vima Therapeutics has announced a major milestone in its drug development pipeline, confirming that...
CSL Invests $1.5B to Expand Illinois Plasma Therapy Facility
KING OF PRUSSIA, Pa., March 9, 2026 CSL Limited, a global biopharmaceutical leader, has announced a $1.5 billion investment...
Aminex Therapeutics Secures FDA Orphan Status for AMXT-1501
SEATTLE — March 11, 2026 Aminex Therapeutics, a clinical-stage biotechnology company focused on developing treatments for rare and difficult-to-treat...
Pierre Fabre Pharmaceuticals Secures FDA Type A Meeting
SECAUCUS, N.J. — March 12, 2026 Pierre Fabre Pharmaceuticals announced that the U.S. Food and Drug Administration has agreed...
BridgeBio BBP-418 Shows Strong Phase 3 Results in LGMD2I/R9
PALO ALTO, CA — March 11, 2026 BridgeBio Pharma announced that its investigational therapy BBP-418 demonstrated consistent efficacy and...
Pretzel Therapeutics PX578 Shows Promise for POLG Disease
WALTHAM, Mass. — March 11, 2026 Pretzel Therapeutics announced new preclinical data for its lead therapeutic candidate PX578 during...
Quoin Pharmaceuticals Advances QRX003 for Netherton Syndrome
Ashburn, Virginia — March 9, 2026 Clinical-stage specialty biopharmaceutical company Quoin Pharmaceuticals Ltd. continues to advance the development of...
Johnson & Johnson Submits TECVAYLI EMA Application
Beerse, Belgium — March 10, 2026 Global healthcare company Johnson & Johnson has announced the submission of a Type...
Alligator Bioscience Secures Patent for Antibody Platform
Lund, Sweden – March 10, 2026 Alligator Bioscience, a clinical-stage biotechnology company focused on tumor-directed immuno-oncology therapies, has announced...